We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Global Neurological Disorder Diagnostics Market Size Share Forecast 2025




 
Neurological disorder diagnostic tools are those used in diagnosis of various neurological disorders. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostics techniques. Imaging techniques such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels and different parts of body, while vitro diagnostic techniques consists of techniques such as biopsy, biomarker, blood test, urine test, and genetic testing.
Market Dynamics
Product launches and approvals of novel neurological diagnostic products is expected to be a major driver for growth of the global neurological disorder diagnostics. For instance, in 2016, Koninklijke Philips N.V. launched its latest Philips IQon Spectral CT in Canada. The latest Philips IQon Spectral CT is the world's first and only spectral detector CT, designed specifically for spectral imaging. With a new dual-layer spectral detector, the IQon Spectral CT has added spectral resolution to conventional CT scanning. Increasing research and development activities for development of novel diagnosis techniques for neurological disorder is also expected to fuel the market growth. For instance, in 2017, researchers from Assistance Publique - Hôpitaux de Paris (AP-HP) in collaboration with ICM researchers (Inserm/CNRS/UPMC) and Metafora Biosystems, developed a diagnostic blood test for De Vivo disease, a rare neurological illness. Increasing prevalence of neurological disorders is also expected to increase demand for diagnostic devices in the near future. For instance, According to World Alzheimer Report 2016, around 47 million people are living with dementia worldwide, and this is expected to increase about three-fold to reach 131 million by 2050. Alzheimer is one of the leading causes of dementia and accounts for an estimated 60% to 80% of all of dementia cases, according to 2018 Alzheimer's Facts and Figures published by Alzheimer's Association.
Key features of the study:
• This report provides in-depth analysis of neurological disorder diagnostics and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global neurological disorder diagnostics based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global neurological disorder diagnostics report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the neurological disorder diagnostics
Detailed Segmentation:
• Global Neurological disorder diagnostics, By Technology :
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
• Global Neurological disorder diagnostics, By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
• Global Neurological disorder diagnostics, By End User:
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
• Global Neurological disorder diagnostics, By Geography:
o North America
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o U.S.
o Canada
o Europe
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Middle East
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o GCC
o Israel
o Rest of Middle East
o Africa
o Technology:
o Imaging
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Biomarker
o Biopsy
o Others
o By Disease Indication:
o Genetic Neurological Disorders
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Paraproteinemic neuropathies
o Others
o By End User
o Hospitals & Clinics
o Diagnostic Centers
o Ambulatory Care Centers
o By Country:
o Central Africa
o South Africa
o North Africa
• Company Profiles
o Siemens Healthineers*
o Company Overview
o Product Portfolio
o Financial Performance
o Key Strategies
o Recent Developments
o Koninklijke Philips N.V.
o General Electric Company
o Esaote SpA
o NeuroLogica Corporation
o Masimo Corporation
o York Instruments Ltd.
o Neusoft Medical Systems
o Canon Medical Systems Corporation
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Technology
o Market Snippet, By Disease Indication
o Market Snippet, By End User
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o PEST Analysis
o Porter's Five Forces Analysis
4. Global Neurological Disorder Diagnostics Market, By Technology, 2016 - 2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Imaging
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Segment Trends
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Nuclear Medicine Imaging
o Positron Emission Tomography (PET)
o Single-Photon Emission Computed Tomography (SPECT)
o Near Infrared Spectroscopic Imaging (NIRS)
o Electroencephalography (EEG)
o Magnetoencephalography (MEG)
o In Vitro Diagnostics
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Biomarker
o Biopsy
o Others
5. Global Neurological Disorder Diagnostics Market, By Disease Indication, 2016 - 2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Genetic Neurological Disorders
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Segment Trends
o Alzheimer's Disease (AD)
o Parkinson's Disease (PD)
o Amyotrophic Lateral Sclerosis (ALS)
o Huntington's Disease (HD)
o Others
o Immunological Neurological Disorders
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Segment Trend
o Multiple Sclerosis
o Others
o Paraneoplastic Syndrome
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Paraproteinemic neuropathies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Segment Trend
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
6. Global Neurological Disorder Diagnostics Market, By End User, 2016 - 2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Hospitals & Clinics
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Diagnostic Centers
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o Ambulatory Care Centers
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
o
7. Global Neurological Disorder Diagnostics Market, By Region, 2016 - 2026 (US$ Mn)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o North America
o Market Size and Forecast, By Technology, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By End User, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
o U.S.
o Canada
o Europe
o Market Size and Forecast, By Technology, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By End User, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Technology, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By End User, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o Market Size and Forecast, By Technology, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By End User, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
o Market Size and Forecast, By Technology, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By End User, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
o Central Africa
o South Africa
o North Africa
o Middle East
o Market Size and Forecast, By Technology, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Disease Indication, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By End User, 2016 - 2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
o GCC
o Israel
o Rest of Middle East
8. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o Siemens Healthineers
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Koninklijke Philips N.V.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o General Electric Company
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Esaote SpA
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o NeuroLogica Corporation
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Masimo Corporation
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o York Instruments Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Neusoft Medical Systems
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Canon Medical Systems Corporation
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 40 market data tables and 42 figures on "Neurological Disorder Diagnostics Market - Global forecast to 2026".

 



Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.